C Henríquez1, T T Riquelme2, D Vera2, F Julio-Kalajzić2,3, P Ehrenfeld4, J E Melvin5, C D Figueroa4, J Sarmiento6, C A Flores2. 1. Instituto de Farmacología, Facultad de Medicina Veterinaria, Universidad Austral de Chile, Valdivia, Chile. 2. Centro de Estudios Científicos (CECs), Valdivia, Chile. 3. Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile. 4. Institutos de Anatomía, Histología y Patología, Universidad Austral de Chile, Valdivia, Chile. 5. Secretory Mechanisms and Dysfunction Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA. 6. Instituto de Fisiología, Facultad de Medicina, Universidad Austral de Chile, Valdivia, Chile.
Abstract
AIM: Neutrophils are the first cells to arrive at sites of injury. Nevertheless, many inflammatory diseases are characterized by an uncontrolled infiltration and action of these cells. Cell migration depends on volume changes that are governed by ion channel activity, but potassium channels in neutrophil have not been clearly identified. We aim to test whether KCa3.1 participates in neutrophil migration and other relevant functions of the cell. METHODS: Cytometer and confocal measurements to determine changes in cell volume were used. Cells isolated from human, mouse and horse were tested for KCa3.1-dependent chemotaxis. Chemokinetics, calcium handling and release of reactive oxygen species were measured to determine the role of KCa3.1 in those processes. A mouse model was used to test for neutrophil recruitment after acute lung injury in vivo. RESULTS: We show for the first time that KCa3.1 is expressed in mammalian neutrophils. When the channel is inhibited by a pharmacological blocker or by genetic silencing, it profoundly affects cell volume regulation, and chemotactic and chemokinetic properties of the cells. We also demonstrated that pharmacological inhibition of KCa3.1 did not affect calcium entry or reactive oxygen species production in neutrophils. Using a mouse model of acute lung injury, we observed that Kca3.1(-/-) mice are significantly less effective at recruiting neutrophils into the site of inflammation. CONCLUSIONS: These results demonstrate that KCa3.1 channels are key actors in the migration capacity of neutrophils, and its inhibition did not affect other relevant cellular functions.
AIM: Neutrophils are the first cells to arrive at sites of injury. Nevertheless, many inflammatory diseases are characterized by an uncontrolled infiltration and action of these cells. Cell migration depends on volume changes that are governed by ion channel activity, but potassium channels in neutrophil have not been clearly identified. We aim to test whether KCa3.1 participates in neutrophil migration and other relevant functions of the cell. METHODS: Cytometer and confocal measurements to determine changes in cell volume were used. Cells isolated from human, mouse and horse were tested for KCa3.1-dependent chemotaxis. Chemokinetics, calcium handling and release of reactive oxygen species were measured to determine the role of KCa3.1 in those processes. A mouse model was used to test for neutrophil recruitment after acute lung injury in vivo. RESULTS: We show for the first time that KCa3.1 is expressed in mammalian neutrophils. When the channel is inhibited by a pharmacological blocker or by genetic silencing, it profoundly affects cell volume regulation, and chemotactic and chemokinetic properties of the cells. We also demonstrated that pharmacological inhibition of KCa3.1 did not affect calcium entry or reactive oxygen species production in neutrophils. Using a mouse model of acute lung injury, we observed that Kca3.1(-/-) mice are significantly less effective at recruiting neutrophils into the site of inflammation. CONCLUSIONS: These results demonstrate that KCa3.1 channels are key actors in the migration capacity of neutrophils, and its inhibition did not affect other relevant cellular functions.
Authors: José Eduardo Da Silva-Santos; Maria Cláudia Santos-Silva; Fernando de Queiroz Cunha; Jamil Assreuy Journal: J Pharmacol Exp Ther Date: 2002-03 Impact factor: 4.030
Authors: Lisa A Simms; James D Doecke; Rebecca L Roberts; Elizabeth V Fowler; Zhen Zhen Zhao; Michael A McGuckin; Ning Huang; Nicholas K Hayward; Penelope M Webb; David C Whiteman; Juleen A Cavanaugh; Ruth McCallum; Timothy H J Florin; Murray L Barclay; Richard B Gearry; Tony R Merriman; Grant W Montgomery; Graham L Radford-Smith Journal: Am J Gastroenterol Date: 2010-04-20 Impact factor: 10.864
Authors: Ivica Grgic; Eva Kiss; Brajesh P Kaistha; Christoph Busch; Michael Kloss; Julia Sautter; Anja Müller; Anuradha Kaistha; Claudia Schmidt; Girija Raman; Heike Wulff; Frank Strutz; Hermann-Josef Gröne; Ralf Köhler; Joachim Hoyer Journal: Proc Natl Acad Sci U S A Date: 2009-08-13 Impact factor: 11.205
Authors: Ted Begenisich; Tesuji Nakamoto; Catherine E Ovitt; Keith Nehrke; Carlo Brugnara; Seth L Alper; James E Melvin Journal: J Biol Chem Date: 2004-09-03 Impact factor: 5.157
Authors: Amber R Philp; Texia T Riquelme; Pamela Millar-Büchner; Rodrigo González; Francisco V Sepúlveda; L Pablo Cid; Carlos A Flores Journal: Sci Rep Date: 2018-06-18 Impact factor: 4.379
Authors: Roland Immler; Wiebke Nadolni; Annika Bertsch; Vasilios Morikis; Ina Rohwedder; Sergi Masgrau-Alsina; Tobias Schroll; Anna Yevtushenko; Oliver Soehnlein; Markus Moser; Thomas Gudermann; Eytan R Barnea; Markus Rehberg; Scott I Simon; Susanna Zierler; Monika Pruenster; Markus Sperandio Journal: Cardiovasc Res Date: 2022-03-25 Impact factor: 13.081
Authors: Génesis Vega; Anita Guequén; Amber R Philp; Ambra Gianotti; Llilian Arzola; Manuel Villalón; Olga Zegarra-Moran; Luis Jv Galietta; Marcus A Mall; Carlos A Flores Journal: JCI Insight Date: 2020-08-20